Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Biogen is a drug manufacturers - general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $157.69 – an increase of 1.08% over the previous week. Biogen employs 7,570 staff and has a trailing 12-month revenue of around $9.6 billion.
| Latest market close | $157.69 |
|---|---|
| 52-week range | $153.62 - $268.30 |
| 50-day moving average | $183.39 |
| 200-day moving average | $208.63 |
| Wall St. target price | $251.70 |
| PE ratio | 14.2866 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $11.06 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $158.71 from 2024-11-25
| 1 week (2024-11-20) | 1.74% |
|---|---|
| 1 month (2024-10-25) | -12.65% |
| 3 months (2024-08-27) | -21.93% |
| 6 months (2024-05-24) | -27.13% |
| 1 year (2023-11-27) | -30.63% |
|---|---|
| 2 years (2022-11-25) | -47.99% |
| 3 years (2021-11-26) | 242.9 |
| 5 years (2019-11-27) | 303.35 |
Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biogen shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 billion.
The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $9.6 billion |
|---|---|
| Operating margin TTM | 20.74% |
| Gross profit TTM | $7.9 billion |
| Return on assets TTM | 4.99% |
| Return on equity TTM | 10.47% |
| Profit margin | 16.81% |
| Book value | $112.28 |
| Market Capitalization | $23 billion |
TTM: trailing 12 months
We're not expecting Biogen to pay a dividend over the next 12 months.
Biogen's shares were split on a 3:1 basis on 17 January 2001 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.
Over the last 12 months, Biogen's shares have ranged in value from as little as $153.62 up to $268.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is -0.061. This would suggest that Biogen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biogen has bucked the trend.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc. ; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.